NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure
Mirikizumab is now recommended by NICE for routine NHS use [...]
Commission sets out 25 policy recommendations to unlock access and [...]
The National Institute for Health and Care Excellence (NICE) has [...]